Rivastigmine transdermal patch ( DrugBank: Rivastigmine )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
13	Multiple sclerosis/Neuromyelitis optica	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03840837 (ClinicalTrials.gov)	May 2, 2019	11/2/2019	Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease	Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease	Parkinson Disease;Parkinson Disease Dementia	Drug: Rivastigmine transdermal patch	University of Maryland, Baltimore	National Institute on Aging (NIA)	Completed	18 Years	N/A	All	31	Phase 4	United States
2	NCT00623103 (ClinicalTrials.gov)	January 2008	14/2/2008	Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)	A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)	Parkinson's Disease Dementia	Drug: Rivastigmine capsule;Drug: Rivastigmine transdermal patch	Novartis	NULL	Completed	50 Years	85 Years	All	583	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00881205 (ClinicalTrials.gov)	April 2009	14/4/2009	Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment	A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase	Multiple Sclerosis;Cognitive Impairment	Drug: Rivastigmine transdermal patch;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	All	86	Phase 4	Germany